COLL
Collegium Pharmaceutical Inc

1,572
Loading...
Loading...
News
all
press releases
Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +3.70% and +4.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates
Inotiv (NOTV) delivered earnings and revenue surprises of +20.00% and +4.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High?
The consensus price target hints at a 33.9% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
News Placeholder
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·2mo ago
News Placeholder
ElectroCore, Inc. (ECOR) Reports Q1 Loss, Misses Revenue Estimates
chainwire·4mo ago
News Placeholder
A Preview Of Collegium Pharmaceutical's Earnings
read more...
Benzinga·10mo ago
News Placeholder
Collegium Pharmaceutical Insider Trades Send A Signal
read more...
Benzinga·1y ago

Latest COLL News

View

Advertisement. Remove ads.

Advertisement. Remove ads.